Four Months of Rifampicin May Be Best Option for Latent TB Four Months of Rifampicin May Be Best Option for Latent TB

Four months of daily rifampicin is"short, safe, and effective" and is likely the best way to achieve the ambitious goal set forth by the World Health Organization (WHO) to treat 30 million patients for latent tuberculosis infection by 2022, TB experts say in Lancet Infectious Diseases.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news